Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225222 | 0.90 | LMNA (0.78) | KMT2AKDM4EMEN1LMNAHTT | |
| SCHEMBL899570 | 0.79 | LMNA (0.67) | KMT2AKDM4EMEN1LMNAHTT | |
| Nucleozin SCHEMBL29360670 | 0.78 | NPC1 (0.61) | KMT2AKDM4ELMNAHTTTSHR | |
| Nucleozin SCHEMBL1225006 | 0.78 | NPC1 (0.61) | KMT2AKDM4ELMNAHTTTSHR | |
| SCHEMBL903133 | 0.78 | LMNA (0.65) | KMT2AKDM4EMEN1LMNAHTT | |
| SCHEMBL902963 | 0.77 | LMNA (0.64) | KMT2AKDM4EMEN1LMNAHTT | |
| SCHEMBL1225454 | 0.76 | LMNA (0.68) | KMT2AKDM4EPOLBMEN1LMNA | |
| SCHEMBL10082093 | 0.76 | LMNA (0.57) | KMT2AKDM4EMEN1LMNAHTT | |
| SCHEMBL898748 | 0.76 | LMNA (0.57) | KMT2AKDM4EPOLBMEN1LMNA | |
| SCHEMBL899632 | 0.76 | LMNA (0.57) | KMT2AKDM4EMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | claimed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | claimed |
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | VERSITECH LIMITED (HK) | 2012-06-14 | — | — | US | claimed |
| EP-2462138-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | Versitech Limited (CN) | 2012-06-13 | — | — | EP | claimed |
| WO-2011147199-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | VERSITECH LIMITED (CN) | 2011-12-01 | — | — | WO | claimed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | claimed |
| WO-2011015037-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | THE UNIVERSITY OF HONGKONG (CN) | 2011-02-10 | — | — | WO | claimed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| US-9212177-B2 | Antiviral compounds and methods of making and using thereof | VERSITECH LIMITED (HK) | 2015-12-15 | — | — | US | disclosed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | disclosed |
| EP-2462138-B1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING | VERSITECH LTD (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | VERSITECH LIMITED (HK) | 2012-06-14 | — | — | US | disclosed |
| EP-2462138-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | Versitech Limited (CN) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142701-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | THE UNIVERSITY OF HONG KONG | 2012-06-07 | — | — | US | disclosed |
| WO-2011147198-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF PROLIFERATIVE DISEASES | VERSITECH LIMITED (CN) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147199-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | VERSITECH LIMITED (CN) | 2011-12-01 | — | — | WO | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | THE UNIVERSITY OF HONG KONG | 2011-09-01 | — | — | US | disclosed |
| WO-2011015037-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THERE OF CROSS REFERENCE TO RELATED APPLICATIONS | THE UNIVERSITY OF HONGKONG (CN) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149715-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, SNRPE, HDLBP | KMT2A 3410/4885KDM4E 4225/4885POLB 406/4885 |
| US-20120142701-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PCNA, MKI67, TP53 | KMT2A 3811/4885KDM4E 4645/4885POLB 78/4885 |
| US-20110212975-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | VIP, H1-3, MAVS | KMT2A 1268/4885KDM4E 974/4885POLB 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.